The estimated Net Worth of Tibor Keler is at least $1.72 million dollars as of 7 December 2022. Tibor Keler owns over 16,860 units of Celldex Therapeutics stock worth over $1,008,396 and over the last 16 years he sold CLDX stock worth over $0. In addition, he makes $707,353 as Executive Vice President and Chief Scientific Officer at Celldex Therapeutics.
Tibor has made over 6 trades of the Celldex Therapeutics stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 16,860 units of CLDX stock worth $46,871 on 7 December 2022.
The largest trade he's ever made was exercising 16,860 units of Celldex Therapeutics stock on 7 December 2022 worth over $46,871. On average, Tibor trades about 2,233 units every 194 days since 2009. As of 7 December 2022 he still owns at least 24,217 units of Celldex Therapeutics stock.
You can see the complete history of Tibor Keler stock trades at the bottom of the page.
Dr. Tibor Keler Ph.D. serves as Executive Vice President and Chief Scientific Officer of the Company. Since May 2003, Dr. Keler has held a number of positions with Celldex, including as a founder, Senior Vice President and Chief Scientific Officer of Celldex, from March 2008 to July 2014, and Vice President, Research and Discovery and Chief Scientific Officer, from May 2003 to March 2008. In addition, he was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. Dr. Keler received his Ph.D. in Microbiology from the University of Pennsylvania.
As the Executive Vice President and Chief Scientific Officer of Celldex Therapeutics, the total compensation of Tibor Keler at Celldex Therapeutics is $707,353. There are 3 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.
Tibor Keler is 61, he's been the Executive Vice President and Chief Scientific Officer of Celldex Therapeutics since 2014. There are 13 older and 11 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
Tibor's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil et Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: